Loading quotes...
Forecast
The analysts' average price target is €39.82 (-20.23%). The median is €51.78 (+3.73%).
| Buy |
4 |
| Hold |
11 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | September 2025 | YoY |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | 0 | - |
| Net profit | -14.98m | - |
| EBITDA | -14.81m | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €1.43bn |
Number of shares | 27.71m |
52-week high/low | €51.80 - €5.06 |
| Dividends | No |
Beta | 0.44 |
P/E ratio | -44.46 |
PEG ratio | -0.67 |
P/B ratio | 10.29 |
P/S ratio | 0.00 |
Company profile
| Name | RAPT Therapeutics Inc |
| CEO | Brian Russell Wong |
| Employees | 67 |
